AI assistant
RHYTHM PHARMACEUTICALS, INC. — Director's Dealing 2024
Mar 19, 2024
30849_dirs_2024-03-19_25c8352b-9725-4eb9-bda3-7d412ab75c9c.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: RHYTHM PHARMACEUTICALS, INC. (RYTM)
CIK: 0001649904
Period of Report: 2024-03-19
Reporting Person: Cramer Pamela J. (Chief Human Resources Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-03-19 | Common Stock | S | 15515 | $39.22 | Disposed | 30005 | Direct |
Footnotes
F1: The sale reported in this Form 4 was effected pursuant to Rule 10b5-1 instruction adopted prior to February 27, 2023 solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $39.07 to $39.25. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.